Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
   Or select

Or become a subscriber

Click here to view
our current issue


Under Lock and Key

Orphan drug designations enable companies to cut R&D costs and secure market exclusivity. Dr Kei Enomoto at RGC Jenkins & Co outlines the incentives and questions whether extra intellectual property protection is needed.

Dr Kei Enomoto, RGC Jenkins & Co (September 2013)

Keywords: Orphan Drug Regulation Orphan designation Market exclusivity Supplementary Protection Certificates (SPCs)

    View full article    |    Back to Discovery Technology section

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |